Ipamorelin: Benefits, Recovery Applications, and Dosing Guide 2026

Ipamorelin is a pentapeptide growth hormone-releasing peptide (GHRP) that selectively binds the ghrelin receptor (GHS-R1a) to stimulate growth hormone release from the anterior pituitary. Developed in the late 1990s, it distinguished itself from earlier GHRPs (GHRP-2, GHRP-6) through superior selectivity — producing clean GH pulses without the cortisol elevation, prolactin release, or intense hunger associated with less selective compounds. This guide covers Ipamorelin's mechanism, research evidence, and the dosing protocols used in recovery and body composition research.

Mechanism of Action

Ipamorelin binds selectively to the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary, triggering pulsatile GH secretion that mimics the natural GH pulse pattern. Unlike GHRP-2 and GHRP-6, it has negligible binding affinity for CRH (corticotropin-releasing hormone) receptors, which explains the absence of cortisol elevation. Its selectivity also extends to prolactin — ipamorelin does not meaningfully increase prolactin at research doses. The result is a clean GH pulse with secondary IGF-1 elevation that supports tissue repair, fat metabolism, and muscle protein synthesis.

Recovery and Body Composition Research

The primary research interest in ipamorelin centres on its effects in recovery and body composition contexts:

• Muscle repair and protein synthesis: Elevated GH and downstream IGF-1 accelerate satellite cell activation and muscle protein synthesis, supporting recovery from training-related microtrauma and surgical tissue repair.
• Connective tissue support: GH/IGF-1 axis activation promotes collagen synthesis in tendons, ligaments, and cartilage — a secondary benefit relevant to musculoskeletal rehabilitation research.
• Fat metabolism: Pulsatile GH release promotes lipolysis in adipose tissue, supporting body recomposition goals in longer-cycle protocols.
• Lean mass retention: During caloric deficit protocols, ipamorelin's anabolic signalling helps preserve lean tissue.

Sleep Quality Effects

Pre-sleep dosing of ipamorelin leverages the natural growth hormone secretion surge that occurs during slow-wave sleep. By augmenting this pulse with exogenous GHS-R1a stimulation, pre-sleep ipamorelin administration deepens the overnight GH release event. Research subjects report improved sleep quality as a consistent secondary endpoint — improved sleep architecture serves as both an independent benefit and a mechanism through which overnight tissue repair is enhanced.

Dosing Protocols

Standard ipamorelin research dosing ranges from 100–300 mcg per injection, administered 1–3 times daily:

• Once daily (pre-sleep): 200–300 mcg, 30–60 minutes before sleep. The minimal protocol — maximises overnight GH pulse augmentation and sleep quality improvement.
• Twice daily: 200 mcg morning (fasted) + 200 mcg pre-sleep. Adds a morning lipolytic and recovery component to the overnight protocol.
• Three times daily: 100–200 mcg morning, post-workout, pre-sleep. Maximum GH pulse frequency for intensive recovery or body composition protocols.

Cycle duration: 8–12 weeks on, followed by 2–4 weeks off to maintain receptor sensitivity.

CJC-1295 Stacking Protocol

The most widely used ipamorelin stack pairs it with CJC-1295 (without DAC), a GHRH analogue. Ipamorelin (GHS-R1a agonist) + CJC-1295 (GHRH receptor agonist) creates synergistic GH release through dual-pathway stimulation — GHRH amplifies the GH pulse that ipamorelin triggers. Studies confirm this combination produces significantly larger GH pulses than either compound alone, making it the standard combination protocol in GH-axis research.

Comparison to GHRP-2 and GHRP-6

Ipamorelin's selectivity is its key advantage over earlier GHRPs. GHRP-2 and GHRP-6 both produce significant cortisol and prolactin elevation alongside GH release — ipamorelin does not. GHRP-6 also causes substantial hunger and appetite stimulation; ipamorelin has negligible appetite effects. For research designs where clean GH axis manipulation without adrenocortical or prolactin confounders is required, ipamorelin is the preferred GHRP.

Frequently Asked Questions

Does ipamorelin raise cortisol?

No. Ipamorelin's selectivity for GHS-R1a without meaningful CRH receptor activity means cortisol elevation is negligible at research doses — a key distinction from GHRP-2 and GHRP-6.

How long before effects become apparent in research subjects?

Sleep quality improvements are often reported within 1–2 weeks. Body composition changes (fat reduction, lean mass retention) require 6–12 weeks of consistent administration to accumulate to measurable levels.

Is ipamorelin banned in competitive sports?

Yes. WADA prohibits all growth hormone-releasing peptides (GHRPs) including ipamorelin under Section S2 (Peptide Hormones, Growth Factors, Related Substances). It is detectable in anti-doping testing.

References

• Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
• Gobburu JV, et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin. Pharmaceutical Research, 16(9), 1412–1416.
• Johansen PB, et al. (1999). Ipamorelin: a new growth hormone-releasing peptide. European Journal of Endocrinology, 140(6), 551–557.